Compare CARG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARG | SUPN |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2017 | 2010 |
| Metric | CARG | SUPN |
|---|---|---|
| Price | $30.82 | $49.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $38.29 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.5M | 720.1K |
| Earning Date | 05-22-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | $316,861,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $13.45 | $23.19 |
| Revenue Next Year | $8.75 | $17.65 |
| P/E Ratio | $19.97 | ★ N/A |
| Revenue Growth | ★ 59.92 | N/A |
| 52 Week Low | $24.65 | $29.16 |
| 52 Week High | $39.42 | $59.68 |
| Indicator | CARG | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 39.98 |
| Support Level | $28.80 | $47.95 |
| Resistance Level | $35.55 | $52.14 |
| Average True Range (ATR) | 1.21 | 2.40 |
| MACD | 0.14 | -0.56 |
| Stochastic Oscillator | 43.61 | 0.85 |
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.